REG - AstraZeneca PLC - AstraZeneca invests $3.5 billion in US

AstraZenecaAnnouncement

12/11/2024 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241112:nRSL8031La&default-theme=true

RNS Number : 8031L  AstraZeneca PLC  12 November 2024

12 November 2024

 

AstraZeneca invests $3.5 billion

in R&D and manufacturing in the United States

 

AstraZeneca today announces $3.5 billion of capital investment in the United
States focused on expanding the Company's research and manufacturing footprint
by the end of 2026. This includes $2 billion of new investment creating more
than a thousand new, high-skilled jobs contributing to the growth of the US
economy.

AstraZeneca's expanding footprint in the US includes, among others:

 

·    A state-of-the-art R&D centre in Kendall Square, Cambridge,
Massachusetts

·    A next generation manufacturing facility for biologics in Maryland

·    Cell therapy manufacturing capacity on the West and East Coasts

·    Specialty manufacturing in Texas

 

Pascal Soriot, Chief Executive Officer, AstraZeneca said: "Our multibillion
dollar investment reflects the attractiveness of the business environment
together with the quality of talent and innovation capabilities here in the
United States. By expanding our R&D and manufacturing footprint, we aim to
enhance the development of cutting-edge therapies and support the United
States leadership in healthcare innovation."

Delivering growth: Ambition 2030

These US investments are the first of a series of important steps to help
deliver AstraZeneca's ambition to achieve $80 billion in Total Revenue by 2030
as set out in May this year
(https://www.astrazeneca.com/investor-relations/astrazeneca-investor-day.html)
. A key element of our strategy is accelerating the Company's development in
the United States. The US is AstraZeneca's largest market, generating 44% of
its Total Revenue.(1)

 

AstraZeneca in the US

AstraZeneca has approximately 17,800 employees working across 17 R&D,
manufacturing and commercial sites spanning 12 states.

 

AstraZeneca (https://www.astrazeneca.com/)

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are
sold in more than 125 countries and used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/)  and follow the
Company on social media @AstraZeneca
(https://gateway.zscalertwo.net/auD?origurl=https:%2f%2fwww.linkedin.com%2fcompany%2fastrazeneca&_ordtok=Mkk3WV5DBDPmQrD4F5MGdGDMZR)

 

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

References

1.     As at Q3 2024 noted in AstraZeneca Q3 Financial Results. Available
at:
https://www.astrazeneca.com/media-centre/press-releases/2024/9m-and-q3-2024-results.html
(https://www.astrazeneca.com/media-centre/press-releases/2024/9m-and-q3-2024-results.html)
. Accessed November 2024.

 

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFFFSSEELSESF